** Shares of cancer drug developer MAIA Biotechnology MAIA.A rise 16.4% to $2.20
** Co says its experimental drug, THIO, helped patients with a type of lung cancer live for a median of 16.9 months, in mid-stage trial
** THIO was generally well-tolerated in patients who had received multiple previous treatments, co says
** Co says it is considering the possibility of accelerated FDA approval of THIO
** THIO gained 66.4% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。